Mesenteric Vascular DiseaseMESMARKNCT07460700
Mesenteric Ischemia Markers Study
A study testing Blood samples in people with Mesenteric Vascular Disease, run by Belarusian State Medical University at 1 site in Belarus.
Trial summary
Vascular bowel disease remains a socially significant and potentially fatal condition (if it develops into AMI), primarily due to delayed diagnosis. Blood biomarkers are theoretically ideal for early risk stratification (like troponins in myocardial infarction). Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Mesenteric Vascular Disease
- What is being tested?
- Blood samples
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- 1 siteBelarus
- Study dates
- 22 Dec 2025to 12 Dec 2026
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- 18 years or older, all sex
- Initial decision, the presence of angio-visualisation of the MA and suspicion of mesenteric arteries diseases
- Patient's consent to participate in the study
- No pregnancy, no history of major operations on MA, the gastrointestinal tract and digestive organs (except appendectomy, endoscopic polypectomy).
Who cannot join
- Consent declined by patient or relatives
- Failure to meet inclusion criteria
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Belarus1 site, 1 recruiting
- Recruiting
Belarusian State Medical University
Minsk
Hleb But-Husaim, PhD, +375256139407, dr.buthusaim@gmail.com
About this study
Official title: Mesenteric Ischemia Markers Study In The Presence Of Mesenteric Arteries Disease
Vascular bowel disease remains a socially significant and potentially fatal condition (if it develops into AMI), primarily due to delayed diagnosis. Blood biomarkers are theoretically ideal for early risk stratification (like troponins in myocardial infarction). However, the existing evidence base is characterized by low quality and high heterogeneity, which hinders their use in clinical practice. Therefore, there is an urgent and unmet clinical need for high-quality, methodologically rigorous research to validate biomarkers in MI. A current study (MESMARK) is to be undertaken to identify combinations of biomarkers that can reliably identify mesenteric ischemia (MI) and distinguish between non-transmural and transmural clinical relevant ischemia.
- Conditions
- Mesenteric Vascular Disease
- Being tested
- Blood samples
- Keywords
- Mesenteric arteries disease, Mesenteric Ischemia, Blood biomarkers
- Medical subject headings
- Mesenteric Ischemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blood samplesDiagnostic test
Blood samples as diagnostic tests are the only intervention in the trial
| Study group | Role | What they receive |
|---|---|---|
| MA data and blood samples data | Other | Patients with MA lesions and suspicion of acute or chronic vascular diseases of the intestine. Patients with suspicion of AMI or CMI are to be included and blood samples are to be collected. Blood samples is the only intervention. Receives: Diagnostic Test: Blood samples |
What is being measured
The primary outcome is the main question the study is designed to answer.
Increasing in the level of mesenteric ischemia (MI) markers above the reference threshold level within 1 day after enrollment in the study
Assessment of serum markers level is intended to identify reliable serum markers or the panel of them as biomarkers for the diagnosis of MI. The endpoint is "increasing in serum marker level above the threshold reference level within 24 hours of objectively suspected MI or not". Markers with elevated above the reference threshold level will be assessed individually and in combination (as a marker panel) later to calculate their sensitivity and specificity in diagnostic of MI. These markers include intestinal fatty acid-binding protein (I-FABP), alpha-glutathione S-transferase (α-GST), ischaemia-modified albumin (IMA), D-lactate, D-dimer, adropin, hypoxia-inducible factor (HIF-1α).
Measured: From enrollment to the 24 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Mar 2026
- Study start22 Dec 2025
- Primary completion12 Sep 2026
- Study completion12 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Mesenteric Vascular DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Blood samples is to be collected from study subjects
- Masking
- None (open label)
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Belarusian State Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hleb But-Husaim, Belarusian State Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07460700
- Sponsor's protocol ID
- 35-20240303-2026
- Acronym
- MESMARK
- Status last verified
- Sep 2026
- First submitted
- 27 Feb 2026
- Last updated
- 23 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No